Logo image of ANGO

ANGIODYNAMICS INC (ANGO) Stock Fundamental Analysis

USA - NASDAQ:ANGO - US03475V1017 - Common Stock

11.26 USD
-0.38 (-3.26%)
Last: 10/6/2025, 9:21:50 PM
11.14 USD
-0.12 (-1.07%)
After Hours: 10/6/2025, 9:21:50 PM
Fundamental Rating

2

Taking everything into account, ANGO scores 2 out of 10 in our fundamental rating. ANGO was compared to 191 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of ANGO have multiple concerns. ANGO is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year ANGO has reported negative net income.
In the past year ANGO has reported a negative cash flow from operations.
ANGO had negative earnings in each of the past 5 years.
In multiple years ANGO reported negative operating cash flow during the last 5 years.
ANGO Yearly Net Income VS EBIT VS OCF VS FCFANGO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M -100M -150M

1.2 Ratios

Looking at the Return On Assets, with a value of -12.13%, ANGO is in line with its industry, outperforming 58.64% of the companies in the same industry.
Looking at the Return On Equity, with a value of -18.58%, ANGO is in the better half of the industry, outperforming 61.26% of the companies in the same industry.
Industry RankSector Rank
ROA -12.13%
ROE -18.58%
ROIC N/A
ROA(3y)-26.67%
ROA(5y)-18.08%
ROE(3y)-40.7%
ROE(5y)-27.1%
ROIC(3y)N/A
ROIC(5y)N/A
ANGO Yearly ROA, ROE, ROICANGO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -20 -40 -60 -80

1.3 Margins

ANGO's Gross Margin of 53.92% is in line compared to the rest of the industry. ANGO outperforms 48.69% of its industry peers.
ANGO's Gross Margin has been stable in the last couple of years.
ANGO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 53.92%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.95%
GM growth 5Y-1.07%
ANGO Yearly Profit, Operating, Gross MarginsANGO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 -40 -60

More info and screens

3

2. Health

2.1 Basic Checks

ANGO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ANGO has been increased compared to 1 year ago.
Compared to 5 years ago, ANGO has more shares outstanding
Compared to 1 year ago, ANGO has a worse debt to assets ratio.
ANGO Yearly Shares OutstandingANGO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M
ANGO Yearly Total Debt VS Total AssetsANGO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

2.2 Solvency

An Altman-Z score of 1.96 indicates that ANGO is not a great score, but indicates only limited risk for bankruptcy at the moment.
ANGO has a Altman-Z score of 1.96. This is in the better half of the industry: ANGO outperforms 60.73% of its industry peers.
A Debt/Equity ratio of 0.03 indicates that ANGO is not too dependend on debt financing.
The Debt to Equity ratio of ANGO (0.03) is better than 69.11% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Altman-Z 1.96
ROIC/WACCN/A
WACC8.74%
ANGO Yearly LT Debt VS Equity VS FCFANGO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M 600M

2.3 Liquidity

A Current Ratio of 2.21 indicates that ANGO has no problem at all paying its short term obligations.
With a Current ratio value of 2.21, ANGO perfoms like the industry average, outperforming 41.36% of the companies in the same industry.
ANGO has a Quick Ratio of 1.40. This is a normal value and indicates that ANGO is financially healthy and should not expect problems in meeting its short term obligations.
ANGO has a worse Quick ratio (1.40) than 62.83% of its industry peers.
Industry RankSector Rank
Current Ratio 2.21
Quick Ratio 1.4
ANGO Yearly Current Assets VS Current LiabilitesANGO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

More info and screens

4

3. Growth

3.1 Past

ANGO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 63.16%, which is quite impressive.
Looking at the last year, ANGO shows a decrease in Revenue. The Revenue has decreased by -3.76% in the last year.
The Revenue has been growing slightly by 2.06% on average over the past years.
EPS 1Y (TTM)63.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%9.09%
Revenue 1Y (TTM)-3.76%
Revenue growth 3Y-2.56%
Revenue growth 5Y2.06%
Sales Q2Q%12.18%

3.2 Future

ANGO is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 54.78% yearly.
ANGO is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.38% yearly.
EPS Next Y-110.8%
EPS Next 2Y17.81%
EPS Next 3Y70.91%
EPS Next 5Y54.78%
Revenue Next Year7.47%
Revenue Next 2Y6.91%
Revenue Next 3Y7.1%
Revenue Next 5Y7.38%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ANGO Yearly Revenue VS EstimatesANGO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 100M 200M 300M
ANGO Yearly EPS VS EstimatesANGO Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 0.2 -0.2 0.4 -0.4 0.6 0.8

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

ANGO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ANGO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ANGO Price Earnings VS Forward Price EarningsANGO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50 -100

4.2 Price Multiples

ANGO's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. ANGO is cheaper than 62.83% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 292.28
ANGO Per share dataANGO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

ANGO's earnings are expected to grow with 70.91% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.81%
EPS Next 3Y70.91%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ANGO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ANGIODYNAMICS INC

NASDAQ:ANGO (10/6/2025, 9:21:50 PM)

After market: 11.14 -0.12 (-1.07%)

11.26

-0.38 (-3.26%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)10-02 2025-10-02/bmo
Earnings (Next)01-06 2026-01-06
Inst Owners94.25%
Inst Owner Change0%
Ins Owners6.51%
Ins Owner Change16.35%
Market Cap462.56M
Analysts84
Price Target18.61 (65.28%)
Short Float %8.59%
Short Ratio7.86
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)99.06%
Min EPS beat(2)75.49%
Max EPS beat(2)122.62%
EPS beat(4)4
Avg EPS beat(4)72.23%
Min EPS beat(4)26.47%
Max EPS beat(4)122.62%
EPS beat(8)7
Avg EPS beat(8)47.73%
EPS beat(12)8
Avg EPS beat(12)9.45%
EPS beat(16)11
Avg EPS beat(16)3.9%
Revenue beat(2)2
Avg Revenue beat(2)3.12%
Min Revenue beat(2)0.41%
Max Revenue beat(2)5.83%
Revenue beat(4)3
Avg Revenue beat(4)1.08%
Min Revenue beat(4)-2.6%
Max Revenue beat(4)5.83%
Revenue beat(8)3
Avg Revenue beat(8)-0.79%
Revenue beat(12)3
Avg Revenue beat(12)-1.47%
Revenue beat(16)5
Avg Revenue beat(16)-0.99%
PT rev (1m)0%
PT rev (3m)16.49%
EPS NQ rev (1m)0%
EPS NQ rev (3m)2.08%
EPS NY rev (1m)0%
EPS NY rev (3m)-36.76%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.31%
Revenue NY rev (1m)0.28%
Revenue NY rev (3m)1.05%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.58
P/FCF N/A
P/OCF N/A
P/B 2.53
P/tB 4.06
EV/EBITDA 292.28
EPS(TTM)-0.14
EYN/A
EPS(NY)-0.09
Fwd EYN/A
FCF(TTM)-0.36
FCFYN/A
OCF(TTM)-0.25
OCFYN/A
SpS7.12
BVpS4.45
TBVpS2.77
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -12.13%
ROE -18.58%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 53.92%
FCFM N/A
ROA(3y)-26.67%
ROA(5y)-18.08%
ROE(3y)-40.7%
ROE(5y)-27.1%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.95%
GM growth 5Y-1.07%
F-Score6
Asset Turnover1.04
Health
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Debt/EBITDA 3.96
Cap/Depr 17.3%
Cap/Sales 1.53%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.21
Quick Ratio 1.4
Altman-Z 1.96
F-Score6
WACC8.74%
ROIC/WACCN/A
Cap/Depr(3y)17.4%
Cap/Depr(5y)17.38%
Cap/Sales(3y)1.57%
Cap/Sales(5y)1.57%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)63.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%9.09%
EPS Next Y-110.8%
EPS Next 2Y17.81%
EPS Next 3Y70.91%
EPS Next 5Y54.78%
Revenue 1Y (TTM)-3.76%
Revenue growth 3Y-2.56%
Revenue growth 5Y2.06%
Sales Q2Q%12.18%
Revenue Next Year7.47%
Revenue Next 2Y6.91%
Revenue Next 3Y7.1%
Revenue Next 5Y7.38%
EBIT growth 1Y29.01%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year129.56%
EBIT Next 3Y70.68%
EBIT Next 5Y53.73%
FCF growth 1Y56.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y64.03%
OCF growth 3YN/A
OCF growth 5YN/A